Literature DB >> 11816253

Different risks for NSAID-induced anaphylaxis.

Eugène P van Puijenbroek1, Antoine C G Egberts, Ronald H B Meyboom, Hubert G M Leufkens.   

Abstract

BACKGROUND: After drugs are marketed, spontaneous reporting systems can provide valuable information regarding the occurrence of suspected adverse drug reactions. The Netherlands Pharmacovigilance Foundation has received a substantial number of anaphylactic reaction reports related to the use of nonsteroidal antiinflammatory drugs (NSAIDs).
OBJECTIVE: To investigate whether the risk of anaphylactic reactions being reported during the use of various NSAIDs is greater than with other classes of drugs and if differences among NSAIDs exist.
METHODS: In a case/noncase design, reporting odds ratios (RORs) were calculated using logistic regression analysis. Cases were defined as reports in which anaphylactic or anaphylactoid reactions were reported; all other reports were considered as noncases. The index group consisted of reports in which NSAIDs were mentioned as the suspected medication; the reference group consisted of all other reports.
RESULTS: Between January 1985 and November 2000, the Netherlands Pharmacovigilance Foundation Lareb received 76 cases concerning anaphylactic reactions to NSAIDs. These drugs are strongly associated with anaphylactic reactions. The ROR adjusted for age, gender, and source of the reports was 9.4 (95% CI 6.9 to 12.7). Anaphylactic reactions associated with the use of naproxen, ibuprofen, and diclofenac were reported disproportionately with respect to other drugs. The corresponding RORs from logistic regression analysis adjusted for age, gender, and reporting source for diclofenac, naproxen, and ibuprofen were 17.2 (95% CI 12.1 to 24.5), 9.1 (95% CI 5.2 to 15.9), and 5.5 (95% CI 2.5 to 11.9), respectively.
CONCLUSIONS: The results of this study strengthen previous findings concerning the relative high risk of developing an anaphylactic reaction during the use of NSAIDs, particularly diclofenac, ibuprofen, and naproxen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11816253     DOI: 10.1345/aph.1A140

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.

Authors:  Roberto Leone; Anita Conforti; Mauro Venegoni; Domenico Motola; Ugo Moretti; Ilaria Meneghelli; Alfredo Cocci; Giulia Sangiorgi Cellini; Stefania Scotto; Nicola Montanaro; Giampaolo Velo
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs.

Authors:  Eva A Berkes
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

3.  Anaphylaxis: an update.

Authors:  Darpan Bhargava
Journal:  J Maxillofac Oral Surg       Date:  2012-05-11

4.  Drug-induced anaphylactic reactions in Indian population: A systematic review.

Authors:  Tejas K Patel; Parvati B Patel; Manish J Barvaliya; C B Tripathi
Journal:  Indian J Crit Care Med       Date:  2014-12

5.  Safety of ceftriaxone in paediatrics: a systematic review protocol.

Authors:  Linan Zeng; Imti Choonara; Lingli Zhang; Song Xue; Zhe Chen; Miaomiao He
Journal:  BMJ Open       Date:  2017-08-21       Impact factor: 2.692

6.  Cyclo-oxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase.

Authors:  Mohammad Bakhriansyah; Ronald H B Meyboom; Patrick C Souverein; Anthonius de Boer; Olaf H Klungel
Journal:  Fundam Clin Pharmacol       Date:  2019-04-22       Impact factor: 2.748

7.  Diclofenac Concentrations in Post-Mortem Specimens-Distribution, Case Reports, and Validated Method (UHPLC-QqQ-MS/MS) for Its Determination.

Authors:  Paweł Szpot; Olga Wachełko; Marcin Zawadzki
Journal:  Toxics       Date:  2022-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.